Welcome to the
Hepatitis B Foundation
Tenofovir for Hepatitis B Remains Safe and Effective Over 7 Years
Dec 9 – Chronic hepatitis B patients treated with tenofovir (Viread) for 7 years continued to maintain viral suppression and liver enzyme normalization, while serological response rates continued to increase, according to a poster presented at AASLD 2013. Read more.
China's Struggle With Hepatitis B Discrimination
Dec 9 – Despite a 2010 law banning hepatitis B screening in job and school admission applications, HBV discrimination abounds in China, and seeking justice remains a challenge. Read more.
Peru: Liver Cancer Like No Other
Dec 9 – Liver cancer is the sixth most common cancer worldwide, most often affecting men over 40, and those with cirrhosis or hepatitis B or C. But in Peru, it also uncharacteristically affects young people who do not have the identified related risk factors. Read more.
Hepatitis B Foundation's Student Research Program
Receives Support from Fulton Bank
Nov 20 – The Hepatitis B Foundation’s (HBF) High School Enrichment Program recently received a $10,000 donation from the Fulton Bank. Read more.
The Hep B Foundation’s Baruch S. Blumberg Institute Hosts the 13th Annual Regional Biotech Conference
Nov 15 – Company leaders gathered at the PA Biotechnology Center to discuss ways to get products to market faster, saving valuable time and money during the process. Read more.
Page last modified December 10, 2013